Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Serum vitamin A, E forms tied to prostate cancer risk
Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.
Serum vitamin A, E forms tied to prostate cancer risk
08 Nov 2023
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
08 Nov 2023
Women face heightened breast cancer risk from poor air quality
Prolonged exposure to air pollution appears to put women at increased risk of breast cancer, according to data from the French E3N cohort.
Women face heightened breast cancer risk from poor air quality
07 Nov 2023
Diabetes, obesity tied to upstaging in renal cell carcinoma
Diabetes and higher body mass index (BMI) contribute to pathological upstaging in renal cell carcinoma, according to a study. Preoperative tumour size, increased age, and male sex are also significantly associated with upstaging.
Diabetes, obesity tied to upstaging in renal cell carcinoma
07 Nov 2023
Adding pembrolizumab to cCRT ups PFS in high-risk locally advanced cervical cancer
In patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, adding pembrolizumab to concurrent chemoradiotherapy (cCRT) significantly improves progression-free survival (PFS) vs cCRT alone, according to results of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study presented at European Society for Medical Oncology Congress 2023 (ESMO 2023).
Adding pembrolizumab to cCRT ups PFS in high-risk locally advanced cervical cancer
06 Nov 2023
Add-on immunotherapy prolongs survival in advanced endometrial cancer
In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.
Add-on immunotherapy prolongs survival in advanced endometrial cancer
03 Nov 2023
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).